Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DCGO Stock Forecast 2025-2026
$1.05
Current Price
$102.70M
Market Cap
Buy 4
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to DCGO Price Targets
+281.1%
To High Target of $4.00
+185.8%
To Median Target of $3.00
-4.7%
To Low Target of $1.00
DCGO Price Momentum
+1.9%
1 Week Change
-5.4%
1 Month Change
-74.3%
1 Year Change
-75.2%
Year-to-Date Change
-81.5%
From 52W High of $5.68
+21.2%
From 52W Low of $0.87
📊 TOP ANALYST CALLS
Did DCGO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if DocGo is one of their latest high-conviction picks.
Latest DCGO Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, DCGO has a bullish consensus with a median price target of $3.00 (ranging from $1.00 to $4.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.05, the median forecast implies a 185.8% upside. This outlook is supported by 4 Buy, 3 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DCGO Analyst Ratings
4
Buy
3
Hold
0
Sell
DCGO Price Target Range
Low
$1.00
Average
$3.00
High
$4.00
Current: $1.05
Latest DCGO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DCGO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 12, 2025 | Canaccord Genuity | Richard Close | Hold | Maintains | $1.50 |
| Aug 21, 2025 | Canaccord Genuity | Richard Close | Hold | Maintains | $1.60 |
| May 12, 2025 | Canaccord Genuity | Richard Close | Hold | Downgrade | $1.45 |
| May 9, 2025 | Needham | Ryan MacDonald | Buy | Maintains | $3.00 |
| Apr 8, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $4.00 |
| Feb 28, 2025 | Needham | Ryan MacDonald | Buy | Maintains | $4.00 |
| Feb 28, 2025 | Stifel | David Grossman | Buy | Maintains | $5.50 |
| Jan 16, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $7.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $5.00 |
| Aug 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $5.00 |
| Aug 8, 2024 | Needham | Ryan MacDonald | Buy | Reiterates | $7.00 |
| May 9, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $5.00 |
| May 9, 2024 | Canaccord Genuity | Richard Close | Buy | Maintains | $5.00 |
| May 9, 2024 | BTIG | David Larsen | Buy | Maintains | $7.00 |
| May 9, 2024 | Needham | Ryan MacDonald | Buy | Maintains | $7.00 |
| Apr 30, 2024 | Stifel | David Grossman | Buy | Maintains | $6.50 |
| Apr 11, 2024 | Canaccord Genuity | Richard Close | Buy | Maintains | $9.00 |
| Apr 10, 2024 | Stifel | David Grossman | Buy | Maintains | $8.00 |
| Apr 10, 2024 | BTIG | David Larsen | Buy | Maintains | $11.00 |
| Feb 29, 2024 | Canaccord Genuity | Richard Close | Buy | Maintains | $10.00 |
DocGo Inc. (DCGO) Competitors
The following stocks are similar to DocGo based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DocGo Inc. (DCGO) Financial Data
DocGo Inc. has a market capitalization of $102.70M with a P/E ratio of 8.5x. The company generates $368.09M in trailing twelve-month revenue with a -14.0% profit margin.
Revenue growth is -48.9% quarter-over-quarter, while maintaining an operating margin of -35.6% and return on equity of -21.1%.
Valuation Metrics
Market Cap
$102.70M
Enterprise Value
$48.94M
P/E Ratio
8.5x
PEG Ratio
0.0x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
-48.9%
Gross Margin
+25.6%
Operating Margin
-35.6%
Net Margin
-14.0%
EPS Growth
-48.9%
Financial Health
Cash/Price Ratio
+71.4%
Current Ratio
2.6x
Debt/Equity
11.3x
ROE
-21.1%
ROA
-9.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
DocGo Inc. (DCGO) Business Model
About DocGo Inc.
What They Do
Provider of mobile and integrated medical care.
Business Model
DocGo Inc. generates revenue by delivering non-emergency medical services directly to patients, leveraging technology for improved healthcare delivery. The company's model focuses on breaking down barriers to access in healthcare, utilizing real-time tracking and remote monitoring to enhance patient experiences and optimize service efficiency.
Additional Information
DocGo plays a vital role in supporting healthcare infrastructure, particularly in underserved areas, and helps alleviate pressure on traditional healthcare facilities. Its innovative approach aims to transform healthcare accessibility and service delivery, making it an essential player in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
3,404
CEO
Mr. Lee Bienstock
Country
United States
IPO Year
2000
Website
www.docgo.comDocGo Inc. (DCGO) Latest News & Analysis
Latest News
HALPER SADEH LLC ENCOURAGES DOCGO INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
1 day ago
Quick Summary
Halper Sadeh LLC is investigating potential fiduciary duty breaches by officers and directors of DocGo Inc. (NASDAQ: DCGO). Shareholders are urged to act promptly.
Why It Matters
Potential breaches of fiduciary duty by DocGo's leadership could lead to legal repercussions, affecting stock value and shareholder rights, creating uncertainty for investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
DocGo Inc. (Nasdaq: DCGO) will participate in the Noble Capital Markets Emerging Growth Conference on December 3rd, featuring CEO Lee Bienstock in 1x1 meetings and a presentation at 1:00 PM ET.
Why It Matters
DocGo Inc.'s participation in upcoming investor conferences signals potential growth opportunities and increased visibility, which may influence investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DocGo Inc. (Nasdaq: DCGO) will participate in the 17th Annual Southwest Ideas Conference on November 19, with CFO Norm Rosenberg presenting at 2:20 PM ET; a webcast will be available.
Why It Matters
DocGo's participation in investor conferences signals transparency and engagement with the investment community, potentially influencing stock interest and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DocGo Inc. (DCGO) will host its Q3 2025 earnings call on November 10, 2025, at 5:00 PM EST, featuring CEO Lee Bienstock and CFO Norman Rosenberg.
Why It Matters
DocGo's Q3 earnings call reveals financial performance and future outlook, impacting stock valuation and investor confidence. Analyst participation indicates interest and scrutiny of the company's results.
Source: Seeking Alpha
Market Sentiment:
Neutral
DocGo Announces Third Quarter 2025 Results
26 days ago
Quick Summary
DocGo Inc. reported Q3 2025 revenue of $70.8 million, down from $138.7 million in Q3 2024, attributed to the wind-down of migrant-related programs.
Why It Matters
DocGo's significant revenue drop signals potential instability and reliance on specific contracts. This may affect future growth, profitability, and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DocGo Inc. (DCGO) reported a quarterly loss of $0.11 per share, missing the consensus estimate of a $0.09 loss, compared to earnings of $0.05 per share a year ago.
Why It Matters
DocGo Inc.'s larger-than-expected quarterly loss signals weaker financial performance, potentially impacting investor confidence and stock valuation negatively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About DCGO Stock
What is DocGo Inc.'s (DCGO) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, DocGo Inc. (DCGO) has a median price target of $3.00. The highest price target is $4.00 and the lowest is $1.00.
Is DCGO stock a good investment in 2026?
According to current analyst ratings, DCGO has 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DCGO stock?
Wall Street analysts predict DCGO stock could reach $3.00 in the next 12 months. This represents a 185.8% increase from the current price of $1.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is DocGo Inc.'s business model?
DocGo Inc. generates revenue by delivering non-emergency medical services directly to patients, leveraging technology for improved healthcare delivery. The company's model focuses on breaking down barriers to access in healthcare, utilizing real-time tracking and remote monitoring to enhance patient experiences and optimize service efficiency.
What is the highest forecasted price for DCGO DocGo Inc.?
The highest price target for DCGO is $4.00 from at , which represents a 281.1% increase from the current price of $1.05.
What is the lowest forecasted price for DCGO DocGo Inc.?
The lowest price target for DCGO is $1.00 from at , which represents a -4.7% decrease from the current price of $1.05.
What is the overall DCGO consensus from analysts for DocGo Inc.?
The overall analyst consensus for DCGO is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are DCGO stock price projections?
Stock price projections, including those for DocGo Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 7:13 AM UTC